Autoimmunity and cancer - Beneficial relationships

Area of Science:

• Immunology
• Oncology
• Autoimmunity

Background:

• Autoimmune diseases involve the immune system attacking self-antigens, often producing autoantibodies.
• These autoantibodies can lead to cellular malfunction or destruction.
• This study explores leveraging these naturally occurring autoantibodies for cancer treatment.

Purpose of the Study:

• To investigate the therapeutic potential of autoantibodies from autoimmune diseases for cancer treatment.
• To demonstrate the efficacy of specific autoantibodies against various cancer types.

Main Methods:

• Purification of autoantibodies from patients with autoimmune disorders (vitiligo, anti-phospholipid syndrome, autoimmune hemolytic anemia, SLE).
• In vitro and in vivo testing of these autoantibodies against corresponding cancer cells (melanoma, erythroleukemia, polycythemia vera, chronic lymphocytic leukemia, lymphoma).
• Evaluation of autoantibody binding specificity to cancer cells.

Main Results:

• Anti-melanocyte antibodies from vitiligo patients showed cytotoxicity against melanoma cells.
• Anti-phosphatidylserine antibodies from anti-phospholipid syndrome patients effectively treated melanoma in mice.
• Anti-red blood cell antibodies demonstrated specific binding to erythroid lineage cells, suggesting potential for hematological malignancies.
• Anti-lymphocyte antibodies showed potential for targeting lymphoproliferative diseases.

Conclusions:

• Autoantibodies from diverse autoimmune diseases represent a valuable source of pre-formed, highly specific agents for cancer immunotherapy.
• These autoantibodies can be used directly, as diagnostic tools, or as carriers for cytotoxic agents.
• The findings support the development of novel cancer therapies based on naturally occurring autoantibodies.